Kite's Yescarta Receives the US FDA's Approval for R/R Follicular Lymphoma
Shots:
- The approval is based on a P-II ZUMA-5 study assessing Yescarta (axicabtagene ciloleucel) in 146 patients aged ≥18rs. with r/r iNHL- prior treated with at least 2L of systemic therapy
- The P-II ZUMA-5 study showed 91% of patients responded to a single infusion of Yescarta- including ~74% of patients in a continued remission @18mos.; mDoR was not yet reached @median follow-up of 14.5 mos. In the safety analysis- grade 3 or higher CRS and neurologic toxicities occurred in 8% and 21% of patients respectively
- Yescarta is the first CAR T-cell therapy approved for indolent follicular lymphoma- follows FDA’s BTD and PR and marks the third approved indication for the therapy
Ref: Gilead | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com